Projects per year
Personal profile
Biography
Dr Sueh-li Lim is a haematologist with interest in all aspects of haematology patient care, encompasing both malignant and non-malignant haematology. Dr Lim completed her clinical haematology training at the Alfred Hospital and Western Health, in addition to laboratory haematology training at Melbourne Pathology. She is passionate about providing patient-focused, holistic care for all patients with haematological disorders.
Her current appointments are at Melbourne Pathology (laboratory haematology), Western Health (clinical haematology), in addition to practicing privately as part of the Melbourne Haematology group
Research area keywords
- Malignant Haematology
- Non-malignant haematology
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Lim, S.-L. (Primary Chief Investigator (PCI))
22/10/25 → 22/10/27
Project: Research
-
A Phase 3, randomized, open-label study of belantamab mafodotin administered in combination with lenalidomide and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (TI-NDMM)- DREAMM-10
Lim, S.-L. (Primary Chief Investigator (PCI))
8/07/25 → 7/07/27
Project: Research
-
A Centralized Platform for Functional High Risk Multiple Myeloma – THE ZEPFHR MM Trial (AMaRC 22-03)
Spencer, A. (Primary Chief Investigator (PCI)), Ho, P. J. (Chief Investigator (CI)), Quach, H. (Chief Investigator (CI)), Hill, G. R. (Chief Investigator (CI)), Reddel, R. (Chief Investigator (CI)), Bingham, N. (Chief Investigator (CI)), Reynolds, J. (Chief Investigator (CI)), Mithraprabhu, S. (Chief Investigator (CI)), Chng, W. J. (Chief Investigator (CI)), Erber, W. (Chief Investigator (CI)), Lim, S.-L. (Chief Investigator (CI)), Bryant, C. (Chief Investigator (CI)), Harrison, S. J. (Associate Investigator (AI)), Le, K. (Associate Investigator (AI)), Henderson, M. (Associate Investigator (AI)), Beer, H. (Associate Investigator (AI)), Vandyke, K. (Associate Investigator (AI)), Kemp, R. (Associate Investigator (AI)), Marks, A. (Associate Investigator (AI)) & Taylor, K. M. D. (Chief Investigator (CI))
1/03/24 → 28/02/29
Project: Research
-
A Randomized , Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel with Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants with Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)
Inam, S. (Chief Investigator (CI)), Malherbe, M. (Project Manager) & Lim, S.-L. (Primary Chief Investigator (PCI))
11/11/23 → 23/12/30
Project: Research
-
A Modular Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0305 as Monotherapy or in Combination With Anticancer Agent(s) in Participants with Multiple Myeloma
Lim, S.-L. (Primary Chief Investigator (PCI)), Kennedy, N. (Project Manager), Auguston, B. (Partner Investigator (PI)) & Quach, H. (Partner Investigator (PI))
22/02/24 → 21/02/26
Project: Research
-
No benefit from daratumumab, bortezomib and dexamethasone (D-Vd) in real-world patients with functional high-risk multiple myeloma: A report from the Myeloma and Related Diseases Registry
Lim, S. L., Wellard, C., Rajagopal, R., Harrison, S. J., Khot, A., Quach, H., Ho, P. J., Moore, E., Wood, E. & Spencer, A., Jan 2026, In: British Journal of Haematology. 208, 1, p. 333-336 4 p.Research output: Contribution to journal › Letter › Research › peer-review
1 Link opens in a new tab Citation (Scopus) -
Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma
Zhao, J., Khong, T., Gorniak, M., Khaled, A., McDonald, Z., Reynolds, J., Mithraprabhu, S., Bingham, N., Lim, S., Wong, D., Johnston, A., Motorna, O., Murphy, N., Quach, H., Yang, L. & Spencer, A., Mar 2025, In: Haematologica. 110, 3, p. 764-767 4 p.Research output: Contribution to journal › Letter › Research › peer-review
Open Access4 Link opens in a new tab Citations (Scopus) -
Real-world outcomes in relapsed refractory multiple myeloma patients exposed to three or more prior treatments: an analysis from the ANZ myeloma and related diseases registry
Lim, S. L., Wellard, C., Moore, E., Harrison, S. J., Hang, Q., Ho, J., Rajagopal, R. & Spencer, A., May 2024, In: Internal Medicine Journal. 54, 5, p. 773-778 6 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access3 Link opens in a new tab Citations (Scopus) -
Response adaptive salvage treatment with daratumumab–lenalidomide–dexamethasone for newly diagnosed transplant-eligible multiple myeloma patients failing front-line bortezomib-based induction therapy—ALLG MM21
Lim, S., Reynolds, J., Quach, H., Hutchinson, A., Kerridge, I., Janowski, W., Bergin, K. & Spencer, A., Sept 2024, In: British Journal of Haematology. 205, 3, p. 900-914 15 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access4 Link opens in a new tab Citations (Scopus) -
Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy
Lim, S.-L., Reynolds, J., Quach, H., Hutchinson, A., Kerridge, I. H., Estell, J. A., Wallington-Gates, C., Kalff, A., Yuen, F. & Spencer, A., 15 Nov 2022, In: Blood. 140, Supplement 1, p. 10174-10176 3 p.Research output: Contribution to journal › Meeting Abstract › peer-review